AMP-activated protein kinase (AMPK) is an important regulator of diverse cellular pathways in the setting of energetic stress. Whether AMPK plays a critical role in the metabolic and functional responses to myocardial ischemia and reperfusion remains uncertain. We examined the cardiac consequences of long-term inhibition of AMPK activity in transgenic mice expressing a kinase dead (KD) form of the enzyme. The KD mice had normal fractional shortening and no heart failure, cardiac hypertrophy, or fibrosis, although the in vivo left ventricular (LV) dP/dt was lower than that in WT hearts. During low-flow ischemia and postischemic reperfusion in vitro, KD hearts failed to augment glucose uptake and glycolysis, although glucose transporter content and insulin-stimulated glucose uptake were normal. KD hearts also failed to increase fatty acid oxidation during reperfusion. Furthermore, KD hearts demonstrated significantly impaired recovery of LV contractile function during postischemic reperfusion that was associated with a lower ATP content and increased injury compared with WT hearts. Caspase-3 activity and TUNEL-staining were increased in KD hearts after ischemia and reperfusion. Thus, AMPK is responsible for activation of glucose uptake and glycolysis during low-flow ischemia and plays an important protective role in limiting damage and apoptotic activity associated with ischemia and reperfusion in the heart.

Introduction
AMP-activated protein kinase (AMPK) is a serine-threonine kinase, which is emerging as an important regulator of diverse cellular pathways in the setting of energetic stress (1, 2). AMPK modulates the rapid activation of major energy-generating metabolic pathways, stimulating the oxidation of FFAs (3, 4) and enhancing glucose uptake and glycolysis (5–9). More chronic activation of AMPK regulates metabolic flux by increasing the expression of genes encoding key metabolic proteins (10–12). In addition, AMPK also modulates integrated cellular processes and is instrumental in mitochondrial biogenesis in skeletal muscle (13, 14).

In the ischemic heart, there is decreased oxidative metabolism of both FFAs and glucose due to the diminished oxygen supply, but increased glucose transport and glycolytic ATP production (15). We have previously hypothesized that AMPK may play a role in enhancing glucose uptake and glycolysis during ischemia (5). Activation of glucose transport in skeletal muscle is dependent on AMPK activation during hypoxia (16–18), and to some extent during contraction (18), although the downstream targets of AMPK in GLUT4 vesicular trafficking are unknown. In the heart, we have demonstrated that pharmacologic activation of AMPK leads to glucose transporter translocation and increased glucose uptake (5). AMPK is also known to phosphorylate and activate 6-phosphofructo-2-kinase (PFK-2), which leads to the production of fructose 2,6-bisphosphate, an activator of glycolysis (6). During reperfusion after ischemia, myocardial FFA oxidation is thought to be increased by AMPK phosphorylation of acetyl-CoA carboxylase (ACC), which inhibits the enzyme and decreases the production of malonyl-CoA, an inhibitor of carnitine palmitoyltransferase-1 (CPT-1) (3, 19); this in turn decreases glucose oxidation through the Randle cycle (20). AMPK likely also modulates the activity of additional cellular pathways in ischemic hearts and those that have undergone ischemia/reperfusion, but it remains uncertain as to whether the overall action of AMPK is beneficial or detrimental in this setting (21, 22).

The overall aim of this study was to directly assess the role of AMPK in the metabolic and functional response of the heart during low-flow ischemia and postischemic reperfusion. Hearts from transgenic mice expressing a kinase dead (KD) mutation of the α2 catalytic subunit of AMPK (18) were examined to investigate whether AMPK deficiency impairs glucose uptake and glycolysis during ischemia and alters FFA oxidation and glucose metabolism during reperfusion. In addition, we assessed the functional consequences of AMPK deficiency on left ventricular (LV) contractile function and on the degree of LV dysfunction, necrosis, and apoptotic activity following ischemia and reperfusion.

Results
Cardiac phenotype of KD mice. Hearts from the KD1 line of KD transgenic mice had sufficient expression of the c-myc–tagged K45R α2 catalytic subunit of AMPK; carnitine palmitoyltransferase-1 (CPT-1); kinase dead (KD); left ventricular (LV); LV developed pressure (LVDp); 6-phosphofructo-2-kinase (PFK-2).

Nonstandard abbreviations used: acetyl-CoA carboxylase (ACC); 5-aminooimidazole-4-carboxamide-1-β-L-ribofuranoside (AICAR); AMP-activated protein kinase (AMPK); carnitine palmitoyltransferase-1 (CPT-1); kinase dead (KD); left ventricular (LV); LV developed pressure (LVDp); 6-phosphofructo-2-kinase (PFK-2).

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest 114:495–503 (2004). doi:10.1172/JCI200419297.
AMPK isoform to effectively replace native AMPK isoforms, as shown by immunoblotting heart extracts (Figure 1). The KD protein migrates slower than the WT α2 isoform on SDS-PAGE because of the c-myc tag. This reduction in the content of native α subunits is similar to findings in skeletal muscle, where expression of the K45R isoform effectively competes with native α isoforms for incorporation into the heterotrimeric AMPK complex and those α subunits that are not bound to β and γ subunits likely are degraded (18). Endothelial cells contain the α1 isoform (23), which may contribute to the α1 protein detected on immunoblots in these hearts with myocyte-specific expression of the KD protein.

Previous studies have demonstrated that hearts from transgenic mice with mutations in genes regulating metabolic pathways can have a number of morphologic abnormalities, including hypertrophy and fibrosis (24–27). The KD hearts were slightly smaller than those of their WT littermates, with approximately 10% reduction of heart weight–to–body weight ratio and a trend toward reduced myocyte diameter (Table 1), but were otherwise morphologically normal. They had no evidence of cardiac fibrosis based on trichrome staining or gross ultrastructural abnormalities based on analysis of electron micrographs (Figure 2).

To examine KD mouse hearts with respect to in vivo LV function, echocardiographic and LV hemodynamic measurements were performed. While the LV end-systolic and end-diastolic dimensions and fractional shortening were similar in KD and WT littermate hearts, the echocardiographic fractional wall thickening was slightly lower in the KD hearts compared with WT hearts (Table 1). The in vivo LV diastolic and systolic pressures were similar in the two groups, but there was mildly decreased LV +dP/dt and –dP/dt in the KD hearts (Table 1). Notably, the KD hearts maintained normal ventricular systolic function and normal LV β-1 adrenergic receptor responses (28). Therefore, the primary effect of KD expression on LV function was a mild reduction of fractional wall thickening.

**Effects of ischemia and reperfusion in AMPK activity.** AMPK activity was measured in α1 and α2 immunoprecipitates at baseline during low-flow ischemia and during reperfusion. Under baseline conditions, KD hearts had negligible α2 activity, but normal baseline α1 activity, despite their reduction in α1 protein (Figure 3). During low-flow ischemia, both α1 and α2 activity increased approximately threefold in the WT hearts, but neither increased significantly in the KD hearts. Taken together, these results indicate that there is complete inactivation of α2 activity, while the small amount of α1 that is present in the heart is maximally active at baseline and is not significantly activated during ischemia. Furthermore, during postischemic reperfusion, α1 and α2 activities remained elevated in the WT hearts, but were similar to baseline in the KD hearts.

**Glucose uptake during ischemia and reperfusion.** While pharmacologic activation of AMPK by 5-aminoimidazole-4-carboxamide-1-β-4-ribonucleoside (AICAR) stimulates the translocation of GLUT4 and increases glucose uptake (5), definitive evidence that AMPK mediates the activation of heart glucose transport during ischemia is lacking. To address this issue, we assessed glucose uptake in WT and KD hearts perfused with glucose and fatty acids and subjected them to low-flow ischemia and reperfusion. In the WT hearts, glucose uptake increased twofold during ischemia and remained elevated during reperfusion (Figure 4A). Although glucose uptake under baseline conditions was normal in KD hearts, there was no increase in glucose uptake during ischemia or reperfusion, supporting a critical role for AMPK in mediating enhanced glucose transport during both ischemia and reperfusion. Increased glucose uptake during ischemia was associated with enhanced glycolysis, as evidenced by increased lactate production in the WT hearts (Figure 4B). In contrast, the failure to increase exogenous glucose uptake resulted in less of an increase in lactate release during ischemia in the KD hearts. While lactate production remained elevated during reperfusion in WT hearts, indicating persistently increased glycolysis, it returned to baseline values in KD hearts.

To exclude the possibility that KD hearts have a more generalized impairment in the activation of glucose uptake, we examined the content of glucose transporters and the ability of insulin to stimulate glucose uptake in these hearts. The total GLUT4 and GLUT1 contents were similar in KD and WT hearts, both at baseline and following ischemia/reperfusion (Figure 4D). When hearts were perfused with insulin (1,000 μU/ml), the glucose uptake increased only in the KD hearts and was not significantly different from WT hearts. These results indicate that AMPK mediates the activation of glucose transport during ischemia and reperfusion.

**Table 1**

Morphologic, hemodynamic, and echocardiographic characteristics of WT and AMPK KD mice

<table>
<thead>
<tr>
<th></th>
<th>WT</th>
<th>KD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Morphologic (n = 16 [WT]; n = 19 [KD])</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BW (g)</td>
<td>40.8 ± 1.2</td>
<td>41.3 ± 1.0</td>
</tr>
<tr>
<td>HW (mg)</td>
<td>270 ± 12</td>
<td>237 ± 11a</td>
</tr>
<tr>
<td>HW/BW (mg/g)</td>
<td>6.74 ± 0.34</td>
<td>5.80 ± 0.33b</td>
</tr>
<tr>
<td>Myocyte diameter (μm)</td>
<td>17.27 ± 1.63</td>
<td>16.27 ± 1.08</td>
</tr>
<tr>
<td><strong>Hemodynamic (n = 5 for both)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV peak systolic pressure (mmHg)</td>
<td>98.9 ± 1.2</td>
<td>92.8 ± 3.5</td>
</tr>
<tr>
<td>LV end-diastolic pressure (mmHg)</td>
<td>7.4 ± 2.8</td>
<td>6.1 ± 0.9</td>
</tr>
<tr>
<td>+dP/dt (mmHg x sec⁻¹)</td>
<td>5,265 ± 135</td>
<td>4,742 ± 128b</td>
</tr>
<tr>
<td>–dP/dt (mmHg x sec⁻¹)</td>
<td>−5,195 ± 89</td>
<td>−4,601 ± 179b</td>
</tr>
<tr>
<td>Heart rate (min⁻¹)</td>
<td>372 ± 21</td>
<td>374 ± 25</td>
</tr>
<tr>
<td><strong>Echocardiographic (n = 10 for both)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wall thickness (mm)</td>
<td>1.07 ± 0.01</td>
<td>1.02 ± 0.01</td>
</tr>
<tr>
<td>LV diastolic diameter (mm)</td>
<td>2.51 ± 0.01</td>
<td>2.83 ± 0.01</td>
</tr>
<tr>
<td>LV systolic diameter (mm)</td>
<td>0.94 ± 0.01</td>
<td>1.18 ± 0.01</td>
</tr>
<tr>
<td>Fractional wall thickening (%)</td>
<td>65.9 ± 1.3</td>
<td>60.7 ± 1.5b</td>
</tr>
<tr>
<td>Fractional shortening (%)</td>
<td>63.2 ± 2.2</td>
<td>58.9 ± 3.7</td>
</tr>
<tr>
<td>Heart rate (min⁻¹)</td>
<td>532 ± 30</td>
<td>534 ± 13</td>
</tr>
</tbody>
</table>

A total of 96 myocytes were measured for WT and 139 for KD hearts. Values are mean ± SEM. *Myocyte diameter was measured on low-power electron micrographs (n = 2 for WT and n = 3 for KD hearts). **P < 0.05. HW, heart weight; BW, body weight.
Effects of ischemia and reperfusion on myocardial glycogen and high-energy phosphate content. Hearts expressing mutations in the γ regulatory subunit of AMPK have high AMPK activity and increased glycogen content (28). Interestingly, under baseline conditions, there was less glycogen in the KD compared with WT hearts (Table 2). The glycogen content decreased mildly after low-flow ischemia and by a similar amount (approximately 4 μmol/g/30 min) in KD and WT hearts. Glycogen returned to baseline values during reperfusion in both KD and WT hearts. These findings suggest that AMPK deficiency does not impair either the mobilization of glycogen during ischemia or its resynthesis during reperfusion.

The content of the high-energy phosphates, ATP and phosphocreatine, was also assessed following baseline perfusion, ischemia, and reperfusion (Table 2). Following baseline perfusion, there were similar levels of ATP and phosphocreatine in WT and KD hearts; there was also a similar decline in the contents of the high-energy phosphates at the end of ischemia. Following reperfusion, ATP content was lower in KD hearts, though it remained depressed in both WT and KD hearts. The phosphocreatine content after reperfusion also tended to be lower in KD hearts (P < 0.07), but returned toward baseline values in both WT and KD hearts.

LV function during ischemia and reperfusion. The KD hearts also demonstrated significantly impaired recovery of postischemic LV contractile function in the setting of ischemia and reperfusion. When perfused in the Langendorff mode, there was a minor decrease in baseline LV contractility, as evidenced by a lower positive and negative dP/dt and a trend toward reduced LV developed pressure (LVDP) in KD compared with WT littermate hearts (Figure 6). During low-flow ischemia, LV contractility decreased markedly in both WT and KD hearts, but the values for LVDP, +dP/dt, and −dP/dt were significantly lower in the KD hearts. The recovery of LV function in the KD hearts was more dramatically impaired during postischemic reperfusion. Specifically, the LVDP, +dP/dt, and −dP/dt were all significantly reduced, indicating diminished LV contractility and relaxation during reperfusion in KD compared with WT hearts (Figure 6). Interestingly, there were significant linear relationships between LVDP and ATP (r = 0.817; P < 0.01) and phosphocreatine (r = 0.673; P < 0.05) content during postischemic reperfusion.

Myocardial injury during ischemia and reperfusion. We next assessed whether the poor recovery of LV function was due to greater myocardial injury in KD than WT hearts. Ischemic injury is mediated in large part through the development of myocardial necrosis, which disrupts the sarcolemma and leads to the release of CK-MB and cTnI into the perfusate. Both CK-MB and cTnI were increased during ischemia and reperfusion in KD hearts (Figures 4A and 4B). The increase in CK-MB and cTnI content during ischemia was of similar magnitude in WT and KD hearts; however, the reperfusion content was significantly higher in KD hearts (P < 0.05).

AMPK activation in the postischemic heart is associated with an increase in fatty acid oxidation by inhibiting ACC and decreasing the production of malonyl-CoA, which inhibits CPT-1 (3)
These results demonstrate that AMPK has a critical role in mediating the metabolic and functional responses of the heart to low-flow ischemia and reperfusion. Specifically, loss of AMPK activity in the KD mouse heart is associated with an inability to augment glucose uptake and glycolysis as well as greater necrosis during low-flow ischemia. Furthermore, loss of AMPK activity has important functional consequences in the reperfused post-ischemic heart, including reduced recovery of LV contractile function, greater necrosis, and an increase in apoptotic activity. Taken together, these results indicate that AMPK has an important cardioprotective effect in the ischemic heart.

Discussion

Previous results have demonstrated that low-flow ischemia increases myocardial glucose uptake by the translocation of glucose transporters from intracellular storage sites to the cell surface (15). Glucose uptake during ischemia is not mediated by the PI3K pathway, which is responsible for insulin-stimulated glucose uptake (5). The current observation that KD hearts failed to augment glucose uptake during ischemia provides strong evidence for the hypothesis that AMPK plays a critical role in stimulating glucose transport in the heart in response to metabolic and ischemic stress (5). Similarly, loss of AMPK activity inhibits hypoxia-stimulated glucose uptake in skeletal muscle (18). Our results also complement recent observations on glucose transport during reperfusion following no-flow ischemia in a transgenic mouse that expresses an α2 D157A mutation in the heart (30). In that model, AMPK deficiency partially inhibited, but did not abolish, the stimulation of deoxyglucose uptake after 10 minutes of global no-flow ischemia. The greater inhibition of glucose uptake in the current experiments may be attributable to greater suppression of AMPK activity in this model, but it also raises the interesting possibility that additional mechanisms, which activate glucose transport, might be recruited during reperfusion following more severe no-flow ischemia. These two studies, taken together, make it extremely unlikely that impairment in ischemic glucose transport is due to nonspecific transgene insertion effects.

Although ischemia-activated glucose uptake was impaired in the KD hearts, insulin-stimulated glucose uptake was normal. This finding indicates that the KD hearts do not have a generalized impairment in the ability to activate glucose transport, implying that glucose transporters and the downstream mediators of GLUT vesicular trafficking are intact. While we found that GLUT4 and GLUT1 expression were normal in the KD hearts, the role of AMPK in modulating heart and skeletal muscle GLUT expression remains incompletely understood. In skeletal muscle, chronic AMPK activation with AICAR (10, 11) or the expression of a constitutively active AMPK catalytic subunit...
(8) leads to the upregulation of GLUT4. However, similarly to our findings in the heart, AMPK deficiency in the KD mouse is not associated with decreased GLUT4 content in skeletal muscle (18). Thus, while increased AMPK might drive GLUT4 expression, AMPK activity does not appear to be required to maintain normal amounts of GLUT transporters in muscle.

This study also demonstrates decreased lactate production during both low-flow ischemia and reperfusion in KD hearts, which is in part the consequence of decreased glucose transport. While glucose transport across the sarcolemma is generally considered to be the flux-regulating step of glucose metabolism (31), there are other potential sites of regulation of glucose metabolism by AMPK. In particular, AMPK is also known to phosphorylate and activate PFK-2 during ischemia (6). Thus, an inability to activate PFK-2 during ischemia may have contributed to the decreased glycolytic flux and reduced lactate production observed in the KD hearts. Although the baseline glycogen concentration was reduced in KD hearts, the amount of glycogen consumed during ischemia was the same as that in WT hearts, suggesting that the diminished lactate production and greater injury was not due to impaired ischemic glycogen mobilization.

In addition to its role during ischemia, these studies demonstrate that AMPK has an important function in regulating myocardial metabolism during the postischemic reperfusion period. AMPK activity remained elevated in WT hearts during reperfusion, with little deactivation even 30 minutes after the reintroduction of normal perfusion. Prolonged elevation of AMPK activity was required for the persistently increased glucose uptake during reperfusion. In addition, AMPK is known to inhibit ACC, presumably leading to decreased malonyl-CoA, increased CPT-1 activity, and exaggerated FFA oxidation during reperfusion after ischemia (3, 19). During reperfusion, fatty acid oxidation rates increased above baseline values in WT hearts, but remained partially depressed in KD hearts, confirming the hypothesis that AMPK mediates increased fatty acid oxidation in the postischemic reperfused heart (3, 19).

Increased postischemic fatty acid oxidation is thought to inhibit glucose oxidation through Randle cycle mechanisms (20), resulting in the shunting of glycolytically derived pyruvate to lactate and effectively uncoupling glycolysis from glucose oxidation (32–34). In the reperfused WT hearts, we observed increases in fatty acid oxidation, glucose uptake, and lactate production, but no change in glucose oxidation compared with baseline. These results are consistent with the uncoupling of glycolysis from glucose oxidation, although a significant fall in glucose oxidation was not evident. In contrast, in the reperfused KD hearts, fatty acid oxidation was lower, glucose uptake and lactate production unchanged, and glucose oxidation was higher compared with baseline. These results suggest less uncoupling between glycolysis and glucose oxidation in the KD hearts, but also may reflect some degree of preferential utilization of exogenous glucose for glycogen synthesis during reperfusion. The replenishment of glycogen was similar in KD and WT hearts during reperfusion, despite the

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>WT</th>
<th>KD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glycogen</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>12.5 ± 1.4</td>
<td>7.2 ± 0.7</td>
</tr>
<tr>
<td>Ischemia</td>
<td>8.5 ± 1.9</td>
<td>3.3 ± 0.9</td>
</tr>
<tr>
<td>Reperfusion</td>
<td>12.6 ± 2.1</td>
<td>6.1 ± 0.5</td>
</tr>
<tr>
<td><strong>ATP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>4.2 ± 0.4</td>
<td>3.7 ± 0.7</td>
</tr>
<tr>
<td>Ischemia</td>
<td>1.9 ± 0.3</td>
<td>1.3 ± 0.1</td>
</tr>
<tr>
<td>Reperfusion</td>
<td>1.7 ± 0.3</td>
<td>1.1 ± 0.2</td>
</tr>
<tr>
<td><strong>Phosphocreatine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>5.1 ± 0.7</td>
<td>3.9 ± 1.0</td>
</tr>
<tr>
<td>Ischemia</td>
<td>2.2 ± 0.8</td>
<td>1.0 ± 0.4</td>
</tr>
<tr>
<td>Reperfusion</td>
<td>4.1 ± 0.7</td>
<td>2.6 ± 0.6</td>
</tr>
</tbody>
</table>

Values (μmol/g wet weight) are reported as the mean ± SEM of five to seven experiments. *P < 0.05 versus WT; **P < 0.05 versus baseline; †P < 0.05 versus ischemia; ‡P < 0.07 versus WT.

### Figure 6

LVDP, heart rate (HR), -dP/dt, and +dP/dt for WT (n = 7) and KD (n = 6) transgenic hearts before, during, and after low-flow ischemia. Horizontal lines identify time points with values that are significantly different (P < 0.05) from t = 0. *P < 0.05 versus WT.
of ATP might be more compromised in the KD hearts. During reperfusion, the content of ATP remained depressed in both WT and KD hearts, but was lower in KD hearts. In addition, during reperfusion, the phosphocreatine content tended to be lower in KD hearts ($P = 0.068$). Taken together with the correlations between the high-energy phosphate content and LV function, these findings suggest that loss of the ability to activate AMPK may result in impaired energy metabolism that is associated with postischemic contractile dysfunction.

Because AMPK increases postischemic fatty acid oxidation, there has been concern that AMPK might contribute to myocardial reperfusion injury by uncoupling glycolysis and glucose oxidation and perpetuating intracellular acidosis (38). In this sense, AMPK deficiency might have been predicted to attenuate myocardial damage in the postischemic reperfused heart (21); however, despite the fact that KD hearts had blunted fatty acid oxidation and less lactate production during reperfusion, they demonstrated increased myocardial injury. These results are consistent with the contention that the metabolic effects of AMPK on glucose transport and glycolysis during low-flow ischemia are beneficial. It seems likely, however, that AMPK may activate additional pathways, which are cardioprotective during ischemia and reperfusion. Chronic lack of AMPK might also alter gene expression in KD hearts, making them more susceptible to ischemic injury. AMPK is also activated by $H_2O_2$ (39), and reactive oxygen species generation during reperfusion may account for the persistent AMPK activation. However, it is unknown whether AMPK modulates pathways involved in the generation and scavenging of reactive oxygen species. The effects of AMPK activation on mitochondrial permeability and function also require further investigation. It is also important to consider that the extent to which AMPK is cardioprotective may depend on the severity and duration of ischemia.

In addition to the greater degree of myocardial necrosis in KD hearts, there was an increase in caspase-3 activity and a greater number of TUNEL-positive nuclei in cardiac myocytes in KD compared with WT hearts, suggesting greater activation of apoptotic pathways. Previous studies have demonstrated that increasing glucose uptake through overexpression of GLUT1 inhibits apoptosis in hypoxic cells (40, 41). The pathway by which AMPK may protect against apoptosis is not known, although increased glucose use also inhibits cytochrome c release from the mitochondria (42). Recent studies in endothelial cells, thymocytes, and astrocytes have also demonstrated that activation of AMPK, either pharmacologically or by overexpression of a constitutively active form of the kinase, can decrease the rate of apoptosis induced by a variety of stimuli (43–45). Although
AICAR has also been shown in some studies to stimulate apoptosis (46, 47), this may reflect a pharmacologic effect unrelated to AMPK activation (47).

While the current experiments suggest that AMPK deficiency has a detrimental effect on the heart during ischemia and reperfusion, whether or not enhanced activation of AMPK might be cardioprotective in this setting remains to be proven. It is interesting to note that a meta-analysis of clinical studies using AICAR in the setting of coronary artery bypass grafting demonstrated modest reductions in early cardiac death, myocardial infarction, and the need for LV assist device support (48). Historically, AICAR was developed as a drug (acadesine) designed to increase extracellular adenosine concentrations and adenosine receptor stimulation in ischemic tissue (49). Although not recognized at the time, it is possible that activation of AMPK may have played a role in these beneficial effects. With the ongoing development of newer agents, which are more specific and potent than AICAR, it will be of interest to further examine whether activation of heart AMPK is cardioprotective.

In this study, the KD hearts had lower baseline glycogen contents than WT hearts, consistent with recent observations of lower glycogen content in skeletal muscle from AMPK-deficient transgenic mice (18, 50). Although there is some evidence that AMPK inhibits, rather than activates, glycogen synthase (51), the exact role of AMPK in modulating glycogen metabolism remains uncertain. It is interesting that myocardial glycogen content is increased in both human and mouse hearts expressing what is thought to be a constitutively active mutant of the AMPK γ subunit (28, 52, 53). These hearts have marked accumulation of glycogen, to the extent that it produces pseudohypertrophy with increased ventricular wall thickness. In some cases, glycogen accumulation is also associated with ventricular pre-excitation characteristic of Wolf-Parkinson-White syndrome (29, 53, 54). In this study we observed slightly smaller hearts in KD mice compared with their WT littermates. The changes in the glycogen content alone cannot explain these differences, however, and further work is needed to assess the effects of chronic AMPK deficiency on heart growth.

In summary, the present studies demonstrate that AMPK has an important role in regulating myocardial metabolism during low-flow ischemia/reperfusion and in limiting ischemic injury and apoptosis during postischemic reperfusion. Specifically, the loss of AMPK function results in impaired glucose uptake and glycolysis, poor recovery of postischemic function, and increased myocyte necrosis and apoptosis. It is unlikely that the beneficial effects of AMPK are limited strictly to metabolic effects during ischemia, and novel downstream targets of AMPK, which might be cardioprotective, need to be identified. While AMPK deficiency appears to be detrimental, further studies will be necessary to determine whether AMPK activators, as they become available, prevent myocardial injury during ischemia and reperfusion.

**Methods**

*Muscle-specific α2 KD AMPK transgenic mouse.* Transgenic mice (C57BL/6, KD1 line) that express a KD rat α2 isoform (K45R mutation), driven in heart and skeletal muscle by the muscle creatine kinase promoter, were studied (18). Male mice were studied at 4–6 months of age. No KD mice developed heart failure when studied out to 1 year. WT littermates served as the control group for comparison in all experiments. All studies were approved by the Yale Animal Care and Use Committee.

**Cardiac phenotype.** Heart weight, including ventricles and atria, was measured and expressed as a percentage of body weight. Sections of KD and WT hearts were fixed with 2% paraformaldehyde and stained with H&E for histology and with trichrome stain to assess the degree of extracellular fibrosis. Heart tissue was also fixed in 2.5% glutaraldehyde by perfusion, processed, and sectioned for electron microscopy as previously described (14) to examine cardiac morphol-ogy, myocyte diameter, and ultrastructure. LV function was assessed echocardiographically with a 15-MHz probe (Philips Medical Systems, Andover, Massachusetts, USA) after inhalation anesthesia (0.5–1% isoflurane). LV cavity dimensions, anterior and posterior wall thicknesses, end-systolic fractional shortening, and percentage of wall thickening were measured from M-mode echocardiograms (55, 56). In addition, direct LV hemodynamic measurements (LV pressure, maximal +dP/dt, minimal –dP/dt) were obtained using a 1.4F micromanometer-tipped pressure transducer catheter (Millar Instruments Inc., Houston, Texas, USA) introduced into the left ventricle through the right carotid artery after anesthesia with xylazine (5 mg/kg) and ketamine (100 mg/kg) (57).

**Mouse heart perfusions.** Isolated mouse hearts were retrogradely perfused with Krebs-Henseleit buffer containing 7 mM glucose, 0.4 mM oleate, 1% BSA, and a low fasting concentration of insulin (10 μU/ml). Initial experiments were performed to determine the rate of glucose transport and glycolysis at baseline, during low-flow ischemia, and during postischemic reperfusion. Hearts were initially perfused at a constant aortic pressure of 80 cmH2O at baseline for 30 minutes, flow was then reduced to approximately 20–25% of baseline for 30 minutes of low-flow ischemic perfusion, and then hearts were reperfused at a constant aortic pressure of 80 cmH2O for an additional 30 minutes. To determine whether the expression of the KD form of AMPK affects insulin stimulation of glucose transport, additional perfusions were performed in which the insulin concentration was increased to 1,000 μU/ml for 30 minutes after baseline perfusion for 30 minutes as described above. Glucose uptake was determined as described below.

A second series of experiments was performed to assess the effects of low-flow ischemia and reperfusion on heart glucose and fatty acid oxidation, LV function, and myocardial injury. In these experiments, constant flow perfusion was achieved using a peristaltic pump to produce low-flow ischemia with approximately 80% flow reduction. Following initial perfusion at 80 mmHg for approximately 5 minutes to flush our residual blood from the heart and allow stabilization, hearts were perfused at a baseline flow of 4 ml/min (30 minutes), ischemia at 0.75 ml/min (30 minutes), and reperfusion at 4 ml/min (30 minutes). These perfusions were performed with radiolabeled glucose and oleate as described below. A fluid-filled latex balloon connected to a solid-state pressure transducer (Millar Instruments Inc.) was inserted into the left ventricle through a left atriotomy to measure pressure. LVDP, the first derivative of LVDP (dP/dt), and heart rate were recorded using a digital acquisition system (ADInstruments, Colorado Springs, Colorado, USA) at a balloon volume that resulted in a baseline LV end-diastolic pressure of 5 mmHg. Hearts were freeze-clamped after either the baseline, ischemia, or reperfusion periods and stored at –80°C until the time of assay.

**Metabolic analysis.** Rates of glucose transport and phosphorylation were determined from the production of tritiated water from [2-3H]glucose (58). Lactate production was determined by measuring the perfusate lactate concentration using an automated analyzer (Stat 2300; Yel-low Springs Instrument Co., Yellow Springs, Ohio, USA). The rate of glucose oxidation was determined by the production of [14C]CO2 from [U-14C]glucose, and the rate of fatty acid oxidation was determined by the production of [3H2]O from [9,10-3H]oleate (59). Glycerogen content was determined from methyl precipitates of KOH-digested tissue using

---

*The Journal of Clinical Investigation*  Volume 114  Number 4  August 2004

---

https://doi.org/10.1172/JCI19297
the amyloglucosidase method (60). ATP and phosphocreatine were determined spectrophotometrically from neutralized perchloric acid extracts of tissue samples (61).

**Analysis of AMPK expression and activity and GLUT4 expression.** Immunoblot analysis of proteins separated by SDS-PAGE and electrophoretically transferred to PVDF membranes was performed to determine the expression of the native α1 and α2 subunits of AMPK and the KD α2 protein. Polyclonal sheep Ab’s to α1 and α2 were generously provided by D. Graham Hardie (University of Dundee, Dundee, United Kingdom) (62). A mAb to the c-myc epitope (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) into the perfusate using commercially available spectrophotometric assays. The degree of apoptotic activity was assessed by measuring caspase-3 activity in tissue homogenates using a commercially available fluorimetric assays. The degree of apoptotic activity was assessed by measuring caspase-3 activity in tissue homogenates using a commercially available fluorimetric assay (62). GLUT4 and GLUT1 expression were determined by immunoblot analysis of crude membrane fractions from heart homogenates using polyclonal Ab’s kindly provided by Samuel Cushman (NIH, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA) (15).

**Analysis of myocyte necrosis and apoptosis.** Myocyte necrosis was assessed by determining the release of creatine kinase (Catalchem Inc., Bridgeport, Connecticut, USA) and lactate dehydrogenase (Sigma-Aldrich, St. Louis, Missouri, USA) into the perfusate using commercially available spectrophotometric assays. The degree of apoptotic activity was assessed by measuring caspase-3 activity in tissue homogenates using a commercially available fluorimetric assay (62). GLUT4 and GLUT1 expression were determined by immunoblot analysis of crude membrane fractions from heart homogenates using polyclonal Ab’s kindly provided by Samuel Cushman (NIH, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA) (15).

**Analysis of AMPK expression and activity and GLUT4 expression.** Immunoblot analysis of proteins separated by SDS-PAGE and electrophoretically transferred to PVDF membranes was performed to determine the expression of the native α1 and α2 subunits of AMPK and the KD α2 protein. Polyclonal sheep Ab’s to α1 and α2 were generously provided by D. Graham Hardie (University of Dundee, Dundee, United Kingdom) (62). A mAb to the c-myc epitope (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) into the perfusate using commercially available spectrophotometric assays. The degree of apoptotic activity was assessed by measuring caspase-3 activity in tissue homogenates using a commercially available fluorimetric assay (62). GLUT4 and GLUT1 expression were determined by immunoblot analysis of crude membrane fractions from heart homogenates using polyclonal Ab’s kindly provided by Samuel Cushman (NIH, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA) (15).

**Analysis of myocyte necrosis and apoptosis.** Myocyte necrosis was assessed by determining the release of creatine kinase (Catalchem Inc., Bridgeport, Connecticut, USA) and lactate dehydrogenase (Sigma-Aldrich, St. Louis, Missouri, USA) into the perfusate using commercially available spectrophotometric assays. The degree of apoptotic activity was assessed by measuring caspase-3 activity in tissue homogenates using a commercially available fluorimetric assay (62). GLUT4 and GLUT1 expression were determined by immunoblot analysis of crude membrane fractions from heart homogenates using polyclonal Ab’s kindly provided by Samuel Cushman (NIH, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA) (15).


